|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Extrapolation to other solid cancers demonstrated highly recurrent and tumor-type-specific indel hotspots targeting the noncoding regions of highly expressed genes defining certain secretory cellular lineages: albumin (ALB) in liver carcinoma, gastric lipase (LIPF) in stomach carcinoma, and thyroglobulin (TG) in thyroid carcinoma.
|
28089356 |
2017 |
|
Thyroid carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas.
|
28137736 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.
|
27236916 |
2016 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The diagnosis of thyroid carcinoma in pleural fluid can be particularly challenging as thyroid transcription factor -1 (TTF-1) which is a marker for carcinoma of thyroid origin is also positive in lung adenocarcinomas (which are more frequently associated with pleural effusions) and thyroglobulin (TG) can often be negative in poorly differentiated/analplastic thyroid carcinomas.
|
27456348 |
2016 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We were not able to confirm earlier positive reports on the clinical value of Tg mRNA measurement for the monitoring of patients treated for thyroid cancer.
|
12542917 |
2003 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
To circumvent these problems, we amplified thyroglobulin messenger ribonucleic acid (mRNA) in peripheral blood using RT-PCR and compared the accuracy of this test to serum thyroglobulin immunoassay in patients with thyroid cancer.
|
9851791 |
1998 |
|
Thyroid carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Falsely elevated thyroglobulin and calcitonin due to rheumatoid factor in non-relapsing thyroid carcinoma: A case report.
|
30702570 |
2019 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
This system may therefore be feasible for gene therapy targeting TG-expressing thyroid carcinomas.
|
9724055 |
1998 |
|
Thyroid carcinoma
|
0.200 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Replication-selective virus-mediated oncolysis is a potential therapy for recurrent, well-differentiated, TG-secreting thyroid cancer that is unresponsive to standard treatment.
|
15797967 |
2005 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We measured serum Tg and Cyfra 21.1 6 to 12 months after primary treatment in 473 DTC patients.
|
28779086 |
2017 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The amplification of thyroglobulin (TG) mRNA in peripheral blood of patients with thyroid cancer has been studied for almost one decade, but its real contribution for diagnosis of cancer relapse has not yet been established.
|
19169488 |
2008 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
All requests for TG estimation in thyroid carcinoma patients should have TG antibody estimated at the same time because of the possibility of interference in the tumour marker assay by the antibody.
|
18176864 |
2008 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The detection of serum thyroglobulin (Tg) by immunoassay is widely used to detect residual, recurring or metastatic thyroid carcinoma tIssue in patients with differentiated thyroid cancer (DTC) after total thyroidectomy and radioiodine therapy.
|
12444888 |
2002 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We measured Tg mRNA in 26 patients undergoing levothyroxine (LT(4)) suppressive therapy after total thyroidectomy for thyroid cancer and in 11 controls.
|
14588101 |
2003 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer.
|
30396251 |
2018 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In contrast, cells of moderately differentiated thyroid cancers contained about two to three times less thyroglobulin mRNA.
|
4005800 |
1985 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Studies analyzing mortality from thyroid cancer should stratify patients into the various risk categories based on full baseline data, including postoperative thyroglobulin levels.
|
28791923 |
2017 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.
|
12224028 |
2002 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This study investigated whether the detection of Tg mRNA in peripheral blood, using reverse transcriptase polymerase chain reaction (RT-PCR), is of value in the biochemical surveillance of patients with thyroid cancer.
|
12782763 |
2003 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Hence, accurate TgAb measurement, in addition to Tg quantification, is crucial for thyroid cancer monitoring.
|
28672730 |
2017 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
TPO mRNA expression in differentiated thyroid carcinomas did not always correlate with the mRNA expression of thyroglobulin, thyroid stimulating hormone receptor, and thyroid transcription factor 1.
|
8691351 |
1996 |
|
Thyroid carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These data showed that circulating Tg mRNA is not only a more sensitive marker of residual thyroid tissue or thyroid cancer than sTg, particularly in patients during T4 therapy and with positive antithyroglobulin antibodies, but also was more sensitive than NIS mRNA in all patients.
|
11061512 |
2000 |
|
Thyroid carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to compare the diagnostic performances of sonography plus suppressed or stimulated Tg in low-risk thyroid cancer.
|
28543974 |
2017 |